Modeling sepsis in the laboratory: Merging sound science with animal well-being

Comparative Medicine

Volumn 58, Issue 2, 2008, Pages 120-128

  Nemzek, Jean A ^a   Hugunin, Kelly M S ^a   Opp, Mark R ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; COMPLEMENT; CYTOKINE; ICOSANOID; THROMBIN;

ANIMAL WELFARE; ANIMAL WELLBEING; ASCENDING COLON; BACTERIUM; BLOOD CELL COUNT; CECUM; CYTOKINE PRODUCTION; DEATH; HEART OUTPUT; IMMUNE RESPONSE; IMPLANTATION; LETHARGY; LEUKOCYTE COUNT; LIGATION; MEDICAL RESEARCH; MODEL; MOTOR ACTIVITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PERITONITIS; PUNCTURE; REFLEX; REVIEW; SEPSIS; SHIVERING; SPECIES; TOXEMIA; VASCULAR RESISTANCE; ANIMAL; DISEASE MODEL; DRUG SCREENING; METHODOLOGY; PATHOPHYSIOLOGY;

ANIMAL WELFARE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; SEPSIS;

EID: 45949107409     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC. 1995. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNFα MAb Sepsis Study Group. J Am Med Assoc 273:934-941.
2. Ahrenholz DH, Simmons RL. 1980. Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surgery 88:41-47.
3. Angele MK, Schwacha MG, Ayala A, Chaudry IH. 2000. Effect of gender and sex hormones on immune responses following shock. Shock 14:81-90.
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310.
5. Back MR, Sarac TP, Moldawer LL, Welborn MB 3rd, Seeger JM, Huber TS. 2000. Laparotomy prevents lethal endotoxemia in a murine sequential insult model by an IL10-dependent mechanism. Shock 14:157-162.
6. Baker CC, Chaudry IH, Gaines HO, Baue AE. 1983. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94:331-335.
7. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709.
8. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. 1987. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653-658.
9. Bone RC, Sprung CL, Sibbald WJ. 1992. Definitions for sepsis and organ failure. Crit Care Med 20:724-726.
10. Brackett DJ, Schaefer CF, Tompkins P, Fagraeus L, Peters LJ, Wilson MF. 1985. Evaluation of cardiac output, total peripheral vascular resistance, and plasma concentrations of vasopressin in the conscious, unrestrained rat during endotoxemia. Circ Shock 17:273-284.
11. Buras JA, Holzmann B, Sitkovsky M. 2005. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 4:854-865.
12. Calvano SE. 2004. Letter to the editor. Shock 22:189-190.
13. Chaudry IH, Wichterman KA, Baue AE. 1979. Effect of sepsis on tissue adenine nucleotide levels. Surgery 85:205-211.
14. Clowes GH Jr, Zuschneid W, Turner M, Blackburn G, Rubin J, Toala P, Green G. 1968. Observations on the pathogenesis of the pneumonitis associated with severe infections in other parts of the body. Ann Surg 167:630-650.
15. Consales G, De Gaudio AR. 2005. Sepsis-associated encephalopathy. Minerva Anestesiol 71:39-52.
16. Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D. 2005. Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 12:60-67.
17. Cracker SH, Eddy DO, Obenauf RN, Wismar BL, Lowery BD. 1981. Bacteremia: host-specific lung clearance and pulmonary failure. J Trauma 21:215-220.
18. Cross AS, Opal SM, Sadoff JC, Gemski P. 1993. Choice of bacteria in animal models of sepsis. Infect Immun 61:2741-2747.
19. De Maio A, Torres MB, Reeves RH. 2005. Genetic determinants influencing the response to injury, inflammation, and sepsis. Shock 23:11-17.
20. Dehring DJ, Crocker SH, Wismar BL, Steinberg SM, Lowery BD, Cloutier CT. 1983. Comparison of live bacteria infusions in a porcine model of acute respiratory failure. J Surg Res 34:151-158.
21. Deitch EA. 1992. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg 216:117-134.
22. Deitch EA. 1998. Animal models of sepsis and shock: a review and lessons learned. Shock 9:1-11.
23. Dienstknecht T, Schwache MG, Kang SC, Rue LW, Bland KI, Chaudry IH. 2004. Sex steroid-mediated regulation of macrophage-monocyte function in a two-hit model of trauma-hemorrhage and sepsis. Cytokine 25:110-118.
24. D'Orio V, Wahlen C, Rodriguez LM, Fossion A, Juchmes J, Halleux J, Marcelle R. 1987. A comparison of Escherichia coli endotoxin single-bolus injection with low-dose endotoxin infusion on pulmonary and systemic vascular changes. Circ Shock 21:207-216.
25. Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D. 1999. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun 67:6603-6610.
26. Ebong SJ, Call DR, Bolgos G, Newcomb DE, Granger JI, O'Reilly M, Remick DG. 1999. Immunopathologic responses to nonlethal sepsis. Shock 12:118-126.
27. Enoh VT, Fairchild CD, Lin CY, Varma TK, Sherwood ER. 2006. Differential effect of imipenem treatment on wild-type and NK cell-deficient CD8 knockout mice during acute intra-abdominal injury. Am J Physiol Regul Integr Comp Physiol 290:R685-R693.
28. Esmon CT. 2004. Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med 32:S219-S222.
29. Evans GF, Snyder YM, Butler LD, Zuckerman SH. 1989. Differential expression of interleukin 1 and tumor necrosis factor in murine septic shock models. Circ Shock 29:279-290.
30. Feterowski C, Emmanuilidis K, Miethke T, Gerauer K, Rump M, Ulm K, Holzmann B, Weighardt H. 2003. Effects of functional Toll-like receptor 4 mutations on the immune response to human and experimental sepsis. Immunology 109:426-431.
31. Feterowski C, Mack M, Weighardt H, Bartsch B, Kaiser-Moore S, Holzmann B. 2004. Chemokine receptor 2 regulates leukocyte recruitment and IL-10 production during acute polymicrobial sepsis. Eur J Immunol 34:3664-3673.
32. Fink MP, Heard SO. 1990. Laboratory models of sepsis and septic shock. J Surg Res 49:186-196.
33. Fink MP, MacVittie TJ, Casey LC. 1984. Effects of nonsteroidal anti-inflammatory drugs on renal function in septic dogs. J Surg Res 36:516-525.
34. Fisher CJ Jr, Dhainaut JF, Opal SM, Fribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. J Am Med Assoc 271:1836-1843.
35. Freise H, Bruckner UB, Spiegel HU. 2001. Animal models of sepsis. J Invest Surg 14:195-212.
36. Galanos C, Freudenberg MA, Reutter W. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 76:5939-5943.
37. Gallos G, Jones DR, Nasr SH, Emala CW, Lee HT. 2004. Local anesthetics reduce mortality and protect against renal and hepatic dysfunction in murine septic peritonitis. Anesthesiology 101:902-911.
38. Goldfarb RD, Clock D, Kumar A, McCarthy RJ, Mei J, Guynn T, Matushek M, Trenholme G, Parrillo JE. 1996. A porcine model of peritonitis and bacteremia simulates human septic shock. Shock 6:442-451.
39. Gomez-Flores R, Weber RJ. 2000. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaque-ductal gray matter. Immunopharmacology 48:145-156.
40. Hansbrough JF, Zapata-Sirvent RL, Bartle EJ, Anderson JK, Elliott L, Mansour MA, Carter WH. 1985. Alterations in splenic lymphocyte subpopulations and increased mortality from sepsis following anesthesia in mice. Anesthesiology 63:267-273.
41. Hilburger ME, Adler MW, Truant AL, Meissler JJ Jr, Satishchandran V, Rogers TJ, Eisenstein TK. 1997. Morphine induces sepsis in mice. J Infect Dis 176:183-188.
42. Hollenberg SM. 2005. Mouse models of resuscitated shock. Shock 24:58-63.
43. Hotchkiss RS, Karl IE. 2003. The pathophysiology and treatment of sepsis. N Engl J Med 348:138-150.
44. Hotchkiss RS, Tinsley KW, Swanson PE, Grayson MH, Osborne DF, Wagner TH, Cobb JP, Coopersmith C, Karl IE. 2002. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 168:2493-2500.
45. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, Karl IE. 2001. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166:6952-6963.
46. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI, Chaudry IH. 2005. Cecal ligation and puncture. Shock 24:52-57.
47. Imamura M, Clowes GH Jr. 1975. Hepatic blood flow and oxygen consumption in starvation, sepsis and septic shock. Surg Gynecol Obstet 141:27-34.
48. Kato T, Hussein MH, Sugiura T, Suzuki S, Fukuda S, Tanaka T, Kato I, Togari H. 2004. Development and characterization of a novel porcine model of neonatal sepsis. Shock 21:329-335.
49. Kinasewitz GT, Chang AC, Peer GT, Hinshaw LB, Taylor FB Jr. 2000. Peritonitis in the baboon: a primate model which simulates human sepsis. Shock 13:100-109.
50. Knapp S, Schultz MJ, van der Poll T. 2005. Pneumonia models and innate immunity to respiratory bacterial pathogens. Shock 24:12-18.
51. Kort WJ, Hekking-Weijma JM, TenKate MT, Sorm V, VanStrik R. 1998. A microchip implant system as a method to determine body temperature of terminally ill rats and mice. Lab Anim 32:260-269.
52. Kozak W, Conn CA, Kluger MJ. 1994. Lipopolysaccharide induces fever and depresses locomotor activity in unrestrained mice. Am J Physiol 266:R125-R135.
53. Krarup A, Chattopadhyay P, Bhattacharjee AK, Burge JR, Ruble GR. 1999. Evaluation of surrogate markers of impending death in the galactosamine-sensitized murine model of bacterial endotoxemia. Lab Anim Sci 49:545-550.
54. Lustig MK, Bac VH, Pavlovic D, Maier S, Grundling M, Grisk O, Wendt M, Heidecke CD, Lehmann C. 2007. Colon ascendens stent peritonitis, a model of sepsis adapted to the rat: physiological, microcirculatory, and laboratory changes. Shock 28:59-64.
55. Maier S, Traeger T, Entleutner M, Westerholt A, Kleist B, Huser N, Holzmann B, Stier A, Pfeffer K, Heidecke CD. 2004. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock 21:505-511.
56. Martucci C, Panerai AE, Sacerdote P. 2004. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 110:385-392.
57. Menges T, Engel J, Welters I, Wagner RM, Little S, Ruwoldt R, Wollbrueck M, Hempelmann G. 1999. Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. Crit Care Med 27:733-740.
58. Molina PE. 2006. Opioids and opiates: analgesia with cardiovascular, haemodynamic, and immune implications in critical illness. J Intern Med 259:138-154.
59. Morrow JD, Opp MR. 2005. Diurnal variation of lipopolysaccharide- induced alterations in sleep and body temperature of interleukin-6-deficient mice. Brain Behav Immun 19:40-51.
60. Natanson C, Danner RL, Fink MP, MacVittie TJ, Walker RI, Conklin JJ, Parrillo JE. 1988. Cardiovascular performance with E. coli challenges in a canine model of human sepsis. Am J Physiol 254:H558-H569.
61. Natanson C, Fink MP, Ballantyne HK, MacVittie TJ, Conklin JJ, Parrillo JE. 1986. Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest 78:259-270.
62. Nemzek JA, Call DR, Ebong SJ, Newcomb DE, Bolgos GL, Remick DG. 2000. Immunopathology of a two-hit murine model of acid aspiration lung injury. Am J Physiol Lung Cell Mol Physiol 278:L512-L520.
63. Nemzek JA, Morrison L, Peterson JE, Bolgos G, Rush H. 2003. Quantification of TNFα and IL6 bioactivity in response to lipopolysaccharide in the degu (Octodon degus). Contemp Top Lab Anim Sci 42:39-42.
64. Nemzek JA, Xiao HY, Minard AE, Bolgos GL, Remick DG. 2004. Humane endpoints in shock research. Shock 21:17-25.
65. Newcomb D, Bolgos G, Green L, Remick DG. 1998. Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity. Shock 10:110-117.
66. Newsom DM, Bolgos GL, Colby L, Nemzek JA. 2004. Comparison of body surface temperature measurement and conventional methods for measuring temperature in the mouse. Contemp Top Lab Anim Sci 43:13-18.
67. O'Suilleabhain C, O'Sullivan ST, Kelly JL, Lederer J, Mannick JA, Rodrick ML. 1996. Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury. Surgery 120:290-296.
68. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Fribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M. 1997. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25:1115-1124.
69. Osuchowski MF, Welch K, Siddiqui J, Remick DG. 2006. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 177:1967-1974.
70. Otto CM. 2007. Clinical trials in spontaneous disease in dogs: a new paradigm for investigations of sepsis. J Vet Emerg Crit Care 17:359-367.
71. . Parker SJ, Watkins PE. 2001. Experimental models of gram-negative sepsis. Br J Surg 88:22-30.
72. Reddy RC, Chen GH, Tekchandani PK, Standiford TJ. 2001. Sepsis-induced immunosuppression: from bad to worse. Immunol Res 24:273-287.
73. Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J. 1996. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24:733-742.
74. Remick DG, Bolgos GE, Siddiqui J. 2003. Inflammatory status in sepsis alters efficacy of interleukin-18 binding protein therapy. Crit Care Med 31:2096-2101.
75. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. 2002. Six at six: interleukin 6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467.
76. Remick DG, Newcomb DE, Bolgos GL, Call DR. 2000. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs cecal ligation and puncture. Shock 13:110-116.
77. Riedemann NC, Guo RF, Ward PA. 2003. The enigma of sepsis. J Clin Invest 112:460-467.
78. Russell WMS, Burch RL. 1959. The principles of humane experimental technique. London: Methuen & Co.
79. Sacerdote P. 2006. Opioids and the immune system. Palliat Med 20 Suppl 1:s9-s15.
80. Saito H, Sherwood ER, Varma TK, Evers BM. 2003. Effects of aging on mortality, hypothermia, and cytokine induction in mice with endotoxemia or sepsis. Mech Ageing Dev 124:1047-1058.
81. Singleton KD, Wischmeyer PE. 2003. Distance of cecum ligated influences mortality, rumor necrosis factor α and interleukin 6 expression following cecal ligation and puncture in the rat. Eur Surg Res 35:486-491.
82. Slotman GJ, Fisher CJ Jr, Bone RC, Clemmer TP, Metz CA. 1993. Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med 21:191-195.
83. Song XM, Li JG, Wang YL, Zhou Q, Du ZH, Jia BH, Ke JJ. 2006. Effects of ketamine on proinflammatory cytokines and nuclear factor kappaB in polymicrobial sepsis rats. World J Gastroenterol 12:7350-7354.
84. Soothill JS, Morton DB, Ahmad A. 1992. The HID50 (hypothermia-inducing dose 50): an alternative to the LD50 for measurement of bacterial virulence. Int J Exp Pathol 73:95-98.
85. Stewart D, Fulton WB, Wilson C, Monitto CL, Paidas CN, Reeves RH, De Maio A. 2002. Genetic contribution to the septic response in a mouse model. Shock 18:342-347.
86. Stiles BG, Campbell YG, Castle RM, Grove SA. 1999. Correlation of temperature and toxicity in murine studies of staphylococcal enterotoxins and toxic shock syndrome toxin 1. Infect Immun 67:1521-1525.
87. Topcu I, Ekici NZ, Isik R, Sakarya M. 2006. The effects of tramadol and fentanyl on gastrointestinal motility in septic rats. Anesth Analg 102:876-881.
88. Toth LA. 2000. Defining the moribund condition as an experimental endpoint for animal research. ILAR J 41:72-79.
89. Turnbull IR, Buchman TG, Javadi P, Woolsey CA, Hotchkiss RS, Karl IE, Coopersmith CM. 2004. Age disproportionately increases sepsis-induced apoptosis in the spleen and gut epithelium. Shock 22:364-368.
90. Vallejo R, de Leon-Casasola O, Benyamin R. 2004. Opioid therapy and immunosuppression: a review. Am J Ther 11:354-365.
91. van Griensven M, Dahlweid FM, Giannoudis PV, Wittwer T, Bottcher F, Breddin M, Pape HC. 2002. Dehydroepiandrosterone (DHEA) modulates the activity and the expression of lymphocyte subpopulations induced by cecal ligation and puncture. Shock 18:445-449.
92. Vender JS, Szokol J, Murphy GS, Nitsun M. 2004. Sedation, analgesia, and neuromuscular blockade in sepsis: an evidence-based review. Crit Care Med 32:S554-S561.
93. Vodovotz Y. 2006. Deciphering the complexity of acute inflammation using mathematical models. Immunol Res 36:237-245.
94. Weighardt H, Kaiser-Moore S, Vabulas RM, Kirschning CJ, Wagner H, Holzmann B. 2002. Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J Immunol 169:2823-2827.
95. Wichterman KA, Baue AE, Chaudry IH. 1980. Sepsis and septic shock: a review of laboratory models and a proposal. J Surg Res 29:189-201.
96. Xiao H, Remick DG. 2005. Correction of perioperative hypothermia decreases experimental sepsis mortality by modulating the inflammatory response. Crit Care Med 33:161-167.
97. Zanetti G, Heumann D, Gerain J, Kohler J, Abbet P, Barras C, Lucas R, Glauser MP, Baumgartner JD. 1992. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor α and to lipopolysaccharide. J Immunol 148:1890-1897.
98. Zantl N, Uebe A, Neumann B, Wagner H, Siewert JR, Holzmann B, Heidecke CD, Pfeffer K. 1998. Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect Immun 66:2300-2309.
99. Zellweger R, Zhu XH, Wichmann MW, Ayala A, DeMaso CM, Chaudry IH. 1996. Prolactin administration following hemorrhagic shock improves macrophage cytokine release capacity and decreases mortality from subsequent sepsis. J Immunol 157:5748-5754.